Cosmos Health Inc. has entered a distribution agreement with International Medical Company (IMC) to expand its Sky Premium Life product line in Qatar. IMC, which owns the largest pharmacy chain in the country, has placed an initial purchase order for 31,000 units. The partnership grants Cosmos Health immediate access to a broad consumer base through IMC's established nationwide retail network.

IMC, founded in 1998, is Qatar's fastest-growing pharmaceutical retailer and distributor. Its retail arm, Kulud Pharmacies, operates over 130 branches with a portfolio of more than 12,000 products. The company employs over 1,400 people across its Sales & Marketing, Pharmacy, and Consumer divisions.

Under the agreement, IMC will manage key functions in the territory, including sales and marketing, regulatory affairs, logistics, supply, and distribution. This move marks a further step in Cosmos Health's international expansion of Sky Premium Life across high-growth Gulf markets.

Greg Siokas, CEO of Cosmos Health, stated that Qatar is one of the Gulf's most dynamic healthcare markets. He emphasized that partnering with IMC and its Kulud Pharmacies network puts Sky Premium Life directly in front of consumers at scale from day one. Siokas noted that this aligns with the company's strategy to pursue high-impact partnerships to accelerate global growth.

Cosmos Health Inc. is a diversified, vertically integrated global healthcare group incorporated in 2009 in Nevada. The company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept, and C-Scrub. Through its subsidiary Can Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union.

Cosmos Health Inc. has advanced its international patent application WO2025108566A1 into the European regional phase and the national phases in the United States, Australia, and Canada. The application, titled "Hydrogel for Body Weight Management," covers proprietary hydrogel technology developed for potential applications in body weight management. The filings follow the acquisition of the patent application from Cloudpharm P.C. by Cana Laboratories S.A., a wholly owned subsidiary of Cosmos Health, on June 8, 2026.

Technology and Mechanism

The CCX0722 platform functions through a mechanical mechanism with no systemic absorption. Taken as a capsule before meals, the dried hydrogel absorbs water in the stomach and swells more than 100-fold into soft gel pieces. These pieces occupy stomach volume to support satiety before naturally passing through the gastrointestinal tract.

Development Timeline

Cosmos Health has executed a methodical development strategy for CCX0722, prioritizing long-term commercial value. Key milestones include:

Strategic Significance

The global weight management market was valued at $190.6 billion in 2025 and is projected to grow to $562.2 billion by 2033, representing a compound annual growth rate (CAGR) of 14.2%. Cosmos Health believes its outright ownership of the CCX0722 intellectual property is a differentiator, as the company controls the manufacturing platform without licensing fees or royalty-sharing obligations.

Future Outlook

The advancement of the patent application supports Cosmos Health's strategy to build an international patent portfolio around proprietary technologies. The company intends to pursue licensing, co-development, and strategic partnership opportunities for the platform. Entry into these jurisdictions does not constitute the grant of a patent, and applications will undergo examination by respective patent authorities.